Purpose: Reports on Achromobacter xylosoxidans ocular infections are increasing, drawing attention to its emerging role in infectious keratitis. The purpose of this study is to report the clinical features, antibiotic sensitivities, and visual outcomes of infectious keratitis secondary to Achromobacter xylosoxidans.
A pproximately 1 million outpatient clinic visits for keratitis occur annually in the United States, of which 76.5% are presumably infectious. 1 Infectious keratitis can result in endophthalmitis, corneal scarring, and permanent vision loss. Gram-positive bacteria followed by gramnegative bacteria are the most common pathogens. 2, 3 In South Florida, Pseudomonas aeruginosa and Serratia marcescens were most commonly isolated in contact lensassociated keratitis. 2 Achromobacter xylosoxidans is an aerobic, nonfermentative, gram-negative rod that is closely related to the Pseudomonas species and has been described in the general medical literature as an infection-causing pathogen in immunocompromised patients. 4, 5 In the past, this organism has rarely been associated with keratitis and endophthalmitis. Nevertheless, reports on ocular infections are increasing, drawing attention to the role of A. xylosoxidans in infectious keratitis. [6] [7] [8] Reddy et al 6 described the largest series of A. xylosoxidans-associated ocular diseases with 8 cases of keratitis and 2 cases of postoperative endophthalmitis. They reported that the main risk factor for A. xylosoxidansassociated keratitis was a previous ocular surgery; none of their patients were contact lens wearers. 6 In a report of corneal ulcers associated with therapeutic contact lens wear, A. xylosoxidans was isolated in less than 4% of cases. 9 The literature is sparse regarding antibiotic susceptibility profiles in A. xylosoxidans ocular infections. This pathogen has been reported to be resistant to most aminoglycosides, ampicillin, aztreonam, and most cephalosporins. 7, 10 Few reports demonstrate susceptibility of A. xylosoxidans to piperacillin, ceftazidime, imipenem, and trimethoprim-sulfamethoxazole. 11, 12 Because it is a gram-negative rod, it is presumably susceptible to fluoroquinolones.
Identifying the risk factors and the susceptibility patterns for A. xylosoxidans is important as prompt treatment can help prevent complications such as corneal scar, endophthalmitis, and the need for therapeutic corneal transplantation. 11, 12 The purpose of this study is to report the clinical settings, antimicrobial susceptibilities, and outcomes of culture-proven A. xylosoxidans infectious keratitis.
MATERIALS AND METHODS
The Ocular Microbiology Laboratory Database at the Bascom Palmer Eye Institute was searched to identify patients with positive corneal cultures for A. xylosoxidans between the years 1987 and 2014. Cultures were obtained after corneal scrapings were done. Isolates were identified using standard microbiologic procedures by experienced laboratory personnel. A positive culture was considered when there was growth of more than 50 colonies on 1 solid medium, 10-50 colonies on 2 or more media, or 1-10 colonies on 1 solid medium and positivity on smears/ thioglycollate broth. All growth had to be on "C" streaks, thus any growth not on "C" streaks was considered a contaminant. Organisms were classified according to usual laboratory criteria. The Ocular Microbiology Laboratory Database was also searched for susceptibility profiles. E-strips (bioMérieux, Inc, Durham, NC) were used to determine the in vitro minimum inhibitory concentration for 90% of isolates (MIC 90 , in micrograms per milliliter) for each isolate. After analyzing the microbiology records, the corresponding medical records of these patients were reviewed for demographics, predisposing factors, clinical presentation, presenting and final visual acuities (VAs), and treatment course and outcomes.
This study was approved by the Institutional Review Board of the University of Miami Miller School of Medicine and complied with the principles outlined in the Declaration of Helsinki.
RESULTS
The study included 28 patients, all of whom demonstrated unilateral keratitis. Twelve patients presented through the years 1987 to 2000 and 16 patients presented from 2001 to 2014.
Patient Demographics and Risk Factors
Female patients accounted for 16 (57.1%) of the total population, and right eyes accounted for 16 (57.1%) of the cases. The mean age at presentation was 60.4 6 22.2 years (range: 15-95). Among the predisposing factors, 8 (28.6%) patients had previous penetrating keratoplasty (PK) for which all except 1 were using topical corticosteroids. Eight (28.6%) patients were contact lens wearers, 3 (10.7%) presented with ocular trauma, 2 cases (7.1%) were secondary to herpes simplex virus, 2 (7.1%) had a keratoepithelial defect as a predisposing factor, 2 (7.1%) had exposure keratopathy, 1 (3.6%) was on corticosteroid treatment because of filamentary keratitis, 1 (3.6%) had a neurotrophic corneal ulcer, and in 1 (3.6%) patient, the site of the infection was adjacent to a bleb.
Microbiology and Antimicrobial Susceptibilities
The antibiotic susceptibilities and MIC 90 values are presented in Table 1 . Only 46.7% of the isolates were susceptible to ciprofloxacin. Susceptibility for ceftazidime was 70.0%. Achromobacter xylosoxidans is intrinsically resistant to aminoglycosides, which is why high resistance rates and high MIC 90 values (suggesting resistance) were documented; only 26.7% and 20.0% of the isolates were sensitive to tobramycin and gentamycin, respectively. All (100%) the isolates were susceptible to piperacillin and ticarcillin. MIC 90 values did not change over the study period, so there has been no change in the frequency of A. xylosoxidans resistance during this time. Concomitant pathogens were identified in 10 (35.7%) patients: 3 had S. marcescens, 2 had P. aeruginosa, 2 had Staphylococcus aureus, and 3 showed a mixed growth pattern of P. aeruginosa and Providencia rettgeri; S. aureus and Streptococcus mitis; and Acinetobacter lwoffii and Stenotrophomonas maltophilia ( Table 2) .
Clinical Presentation and Treatment
Data for each patient are summarized in Table 2 . Mean time from symptoms to presentation in the clinic was 13.3 6 13.0 days (range: 1-42 d). Mean VA on presentation was 20/ 730 6 20/210 (range: 20/20 to no light perception). In 20 (71.4%) patients, VA was 20/100 or worse. Corneal infiltrate was central or paracentral in 23 (82.1%) patients at presentation, and hypopyon was present in 7 (25.0%) patients. Fluoroquinolones were the initial treatment of choice, often accompanied by fortified vancomycin. Fortified tobramycin and polymyxin B/trimethoprim were other common treatments.
Clinical Outcomes
Clinical outcomes for each patient are shown in Table 2 . The mean time from the initial treatment until resolution and completion of treatment was 7.7 6 5.5 weeks (range: 0.3-20 wk). Mean VA at the last follow-up visit was 20/600 6 20/280 
DISCUSSION
In the current study we found that infectious keratitis resulting from A. xylosoxidans has poor VA outcomes with a significant number of patients requiring therapeutic PK or conjunctival flap. Important risk factors for A. xylosoxidans keratitis include corneal graft, contact lens wear, and corticosteroid treatment. Although a few case reports and small case series were published in the past, 6, [11] [12] [13] [14] [15] [16] [17] to our knowledge this study represents the largest case series and review of culture-positive infectious keratitis caused by A. xylosoxidans. It was previously reported that the most common predisposing factor for A. xylosoxidans corneal ulcers is a prior PK. 14, 18 Reddy et al 6 reported this factor to be present in 6 of 8 patients with infectious keratitis. In a recent microbiology study, cases and lenses of patients with mild keratitis or corneal ulcer were tested using cultureindependent methods. Achromobacter xylosoxidans was a predominant bacteria identified, pointing out its potential emerging role in factious keratitis. 8 Other studies have described immunosuppression therapy including topical corticosteroids as being a common predisposing factor. 6, 12, 19 In the current study, prior PK and topical corticosteroids were found to be important risk factors. Additionally, the importance of contact lens wear in this setting was documented, as nearly one third of our patients were contact lens wearers.
The clinical diagnosis of microbial keratitis often relies on the history and the morphologic features of corneal inflammation. 20 On a large survey performed among ophthalmologists, most reported fourth-generation fluoroquinolones as their first treatment of choice for presumed bacterial keratitis. 21 Forster 22 recommended fourth-generation fluoroquinolones for milder forms of bacterial keratitis and fortified aminoglycosides as the empirical treatment for more aggressive keratitis. Park et al 7 suggested that ceftazidime and amikacin may best serve as first-line treatment for suspected bacterial keratitis. In our institute, the treatment strategy was determined by the individual ophthalmologist, and no standardized protocol was followed. We found that fluoroquinolones followed by fortified aminoglycosides were the most common initial antibiotic regimen before microbial identification and susceptibility results. However, the A. xylosoxidans isolates were highly resistant to ciprofloxacin, gentamicin, and tobramycin with high MIC 90 values of 8, 16, and 16 mg/mL, respectively. Resistance of A. xylosoxidans to fluoroquinolones in ocular infections was previously reported. 6 Although others reported a 90% sensitivity rate, we found that only 70% of the isolates were susceptible to ceftazidime. 6 All (100%) the tested isolates were sensitive to the beta-lactams piperacillin and ticarcillin with MIC 90 values of 8 and 16 mg/mL, which are in the limits of susceptibility. This study is the first to report the MIC 90 values for A. xylosoxidans keratitis.
Although both A. xylosoxidans and P. aeruginosa are closely related genotypically and microbiologically, their clinical presentation differs. For example, in cystic fibrosis patients, A. xylosoxidans pneumonia is a smoldering disease when compared with P. aeruginosa, which elicits more rapid lung damage. 23, 24 In our study, infection with A. xylosoxidans was subacute with the existence of symptoms for an average of 2 weeks before presentation, mainly with mild pain and discomfort. This is as opposed to P. aeruginosa keratitis where the clinical course is rapid and symptoms have been reported to begin at an average of 4 days before the patient presents. 25 The poor VA outcomes and necessity for therapeutic corneal transplantation or conjunctival flap in 6 patients reported in the current study can be partially explained by the fact that corneal infection by A. xylosoxidans is insidious in onset, resulting in initially subclinical symptomatology, leading patients to seek medical attention relatively late in the course of infection. 8 In addition, the initial treatment usually included fluoroquinolones or aminoglycosides which was, in many instances, ineffective. Finally, many patients had a history of a compromised preinfection ocular surface, resulting in lower initial VAs.
Nine patients were treated with fluoroquinolones and/or aminoglycosides. Only in 3 of them (patients 12, 17, and 25; Table 2 ), the infection resolved without significant scaring and without the need for surgical intervention such as therapeutic keratoplasty. In 2 of these patients, concomitant pathogens were identified. It is possible that A. xylosoxidans was not the primary pathogen in these cases, which may explain the fact that the keratitis responded well to the fluoroquinolone treatment. In the third patient (no. 17; Table  2 ), the infection was mild with good presenting and final VAs. Topical treatment in this case was short-course fourthgeneration fluoroquinolone. Susceptibility testing of a fourthgeneration fluoroquinolone was not done in our study. Although ciprofloxacin is surrogate for fluoroquinolones, we cannot rule out that in A. xylosoxidans keratitis fourthgeneration fluoroquinolones has a better therapeutic effect than the second-generation fluoroquinolones.
The limitations of our study include its retrospective design and the use of positive corneal scraping cultures as an inclusion criteria for the study, which might have excluded cases with false-negative culture results. Because our institute is a tertiary referral center, few patients continued follow-up with their local ophthalmologist, so their full clinical course was not available for review. Despite these limitations, this study provides important data from a relatively large case series regarding the clinical characteristics, antimicrobial susceptibility patterns, and MIC 90 data for A. xylosoxidans infectious keratitis. In conclusion, A. xylosoxidans infection should be considered in patients with slowly progressive gram-negative keratitis and smoldering symptoms who are known to be contact lens wearers, have a corneal graft, or use topical corticosteroids. For many ophthalmologists, fluoroquinolones and aminoglycosides are the first empirical treatment of choice for presumed bacterial keratitis. It is important to know that these antimicrobials are not an appropriate treatment for A. xylosoxidans keratitis. Instead, compounded piperacillin or ticarcillin eye drops should be considered. However, as the topical regimen of these antibiotics was not applied, further studies are needed to define their clinical application.
